Crown Bioscience Increases APAC Capacity with New Facility in Zhongshan, China
27.10.2020 15:00:00 EET | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/
CrownBio's New Zhongshan, China Facility (Photo: Business Wire)
In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.
The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.
“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.
A site opening event and ribbon cutting ceremony will take place on October 30th 2020.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.jsrlifesciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005098/en/
Contact information
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC and Xsolis’ Strategic Partnership to Tackle Inefficiencies in Healthcare Decision-Making with AI2.6.2026 15:38:00 EEST | Press release
HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602462348/en/ HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Across healthcare systems, determining whether a treatment is medically necessary, what level of care a patient requires, and whether that care will be approved remains a slow, manual, and often inconsistent process. Known as utilization management, this function sits at the heart of healthcare operations—but is still heavily reliant on fragm
Perpetuals Reports $ 4.5 Billion in UpsideOnly Volume and Signs Exchange Agreement With Datavault AI for Tokenized Commodities2.6.2026 15:00:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC) today reported strong early results for its breakout UpsideOnly trading and market prediction platform and announced an agreement with Datavault AI Inc. (Nasdaq: DVLT) to list tokenized real-world commodity assets on the Perpetuals platform. In its first two weeks, traders flocked to the UpsideOnly platform, attracting more than 30,000 active users, generating $4.5 billion in cumulative platform volume across 186,000 fills and 25 instruments. Reflecting the widespread demand for a risk-free product, users came from 185 different countries. Surprisingly, gold was the top instrument with $1.4 billion in volume, outpacing bitcoin at $1.2 billion with precious metals accounting for roughly 35 percent of total platform activity. UpsideOnly is the first trading and market prediction platform where users can't lose. Traders make predictions across global markets and share in profits when those predictions are validated by Perpetuals's proprietary AI, without e
Phenom Positioned as Strategic Leader in Fosway 9-Grid™ for Talent Acquisition Sixth Consecutive Year2.6.2026 15:00:00 EEST | Press release
Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602897994/en/ Phenom has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. The execution gap is well documented. Fosway’s recent AI Market Assessment for Talent Acquisition found that only 27% of AI features claimed by talent acquisition vendors are actu
How Fit Analytics Innovation Reclaimed its Independence to Build the Future of AI Commerce2.6.2026 14:47:00 EEST | Press release
With today’s launch of the AI Shopping Assistant, Fit Analytics Innovation moves beyond the AI-hype-cycle to deliver the conversational guidance modern apparel shoppers crave. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602315868/en/ AI Shopping Assistant - Fit Analytics Innovation Two years ago, Fit Analytics Innovation did the unthinkable: they bought themselves back. Following a high-profile acquisition by Snap Inc., the management team recovered the award-winning Fit Finder and secured sixteen years of expertise and data insights. That bet on independence has culminated in the launch of the AI Shopping Assistant, the latest module available as part of their expanded product suite. Delivering Performance Over P.R. Unlike "overnight" AI startups rushing for market share, Fit Analytics has utilized its independence to prioritize depth over hype. The resulting AI Shopping Assistant is a native evolution of the company’
Kinaxis Introduces Forward Deployed Engineering to Help Enterprises Turn Decisions into Outcomes2.6.2026 14:01:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today introduced Forward Deployed Engineering (FDE), a new engagement model designed to help enterprises operationalize AI and translate decisions into measurable business outcomes. FDE reflects the broader Kinaxis vision for operational orchestration, an approach that coordinates signals, decisions, actions and learnings across the business fast enough to change outcomes. The opening keynote at Kinexions, the company’s global customer conference, delivered by CEO Razat Gaurav will be livestreamed globally on June 2 @ 11:30 am EST via LinkedIn Live. This approach combines a unified data foundation with semantic intelligence that understands the relationships, dependencies, and trade-offs that shape enterprise operations. Together, these capabilities help organizations move beyond isolated decision-making to coordinated execution, connecting data, systems, teams, and actions across the enterprise. Tradi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom